EGI
RYTM icon

EAM Global Investors’s Rhythm Pharmaceuticals RYTM Stock Holding History

EAM Global Investors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-56,936
Closed -$3.19M – 142
2024
Q4 		$3.19M Buy
+56,936
New +$3.14M 0.57% 102
2023
Q1 		– Sell
-62,623
Closed -$1.82M – 171
2022
Q4 		$1.82M Sell
62,623
-16,353
-21% -$420K 0.47% 99
2022
Q3 		$1.94M Buy
+78,976
New +$1.47M 0.51% 77

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM Global Investors's RYTM Position: Q1 2025 in Review

EAM Global Investors sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2025, closing a stake of 56,936 shares — an estimated $3.19M sold.

EAM Global Investors first reported a position in RYTM in Q3 2022 and held it in 3 quarters. The position peaked at $3.19M in Q4 2024. 228 funds tracked by Wall St. Rank hold RYTM as of Q1 2025.

  • EAM Global Investors reported no remaining Rhythm Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • EAM Global Investors sold 56,936 Rhythm Pharmaceuticals shares in Q1 2025, an estimated $3.19M.
  • EAM Global Investors first reported a position in Rhythm Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • EAM Global Investors's Rhythm Pharmaceuticals position peaked at $3.19M in Q4 2024.
  • 228 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2025.

Based on EAM Global Investors's 13F filing for Q1 2025, filed 12 May 2025.